Streamlining Neurology CVS Caremark Integration for Prior Authorization Workflows

The Unique PA Landscape for Neurology with CVS Caremark

Neurology practices frequently encounter PA requirements for high-cost, high-impact therapies and diagnostics managed by PBMs. CVS Caremark, as a major PBM, plays a significant role in determining coverage for medications such as MS disease-modifying therapies (DMTs), CGRP migraine biologics, and specific Alzheimer's disease treatments. Navigating their specific clinical criteria and submission channels, whether via payer portal, X12 278, or other ePA methods, can consume substantial administrative resources.

High-Volume Neurology PA Categories Impacted by Caremark Policies

• **MS Disease-Modifying Therapies (DMTs):** Including high-efficacy agents like ocrelizumab and natalizumab, and oral DMTs such as ozanimod, which often require step therapy compliance and detailed documentation of McDonald criteria and EDSS scores.
• **CGRP Migraine Biologics:** Monoclonal antibodies (e.g., erenumab, fremanzumab) and oral gepants (e.g., atogepant) for chronic migraine prevention, frequently subject to prior preventive trial failures and headache diary submission.
• **Alzheimer's Disease Therapeutics:** Newer anti-amyloid antibodies like lecanemab, demanding specific amyloid imaging or CSF biomarker confirmation, APOE genotyping, and MRI screening protocols.
• **Botox for Chronic Migraine/Spasticity:** OnabotulinumtoxinA and similar agents for specific indications, requiring documentation of prior therapy trials and adherence to dosing protocols.
• **Advanced Imaging:** Brain MRI, MR angiography, and amyloid PET scans, which are crucial for diagnosis and monitoring, and often require PA through medical benefit plans associated with CVS Health.

Addressing Common Denial Reasons in Neurology PAs to Caremark

Many neurology PA denials from PBMs like CVS Caremark stem from specific documentation gaps or unmet step therapy requirements. For MS DMTs, denials often occur due to non-compliance with payer-mandated moderate-efficacy DMT trials before high-efficacy agents. Similarly, CGRP migraine prevention often faces denial if prior oral preventive trials are not adequately documented. For Alzheimer's anti-amyloid antibodies, missing amyloid biomarker confirmation is a frequent issue, directly impacting patient access to critical treatments.

Klivira's Approach to Optimize Neurology CVS Caremark Integration

Klivira's platform is engineered to streamline the specific complexities of neurology prior authorizations with CVS Caremark. We integrate directly with your EMR, leveraging SMART on FHIR capabilities to extract necessary clinical data, such as McDonald criteria for MS, headache diaries for migraine, and amyloid confirmation results for Alzheimer's therapies. Our system automates the submission process via appropriate channels, including X12 278 electronic prior authorization, reducing manual effort and accelerating approval times for specialty drugs and advanced imaging.

Enhanced Workflow for Chronic Neurology Treatments

Neurology often involves chronic treatments requiring periodic re-authorization, such as for MS DMTs and Botox. Klivira's platform manages these cyclical PAs, proactively tracking re-authorization dates and initiating the process with CVS Caremark before existing approvals expire. This ensures continuity of care and minimizes administrative burden, allowing clinical staff to focus on patient care rather than repetitive paperwork.